Ann: Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund, page-130

  1. 30,691 Posts.
    lightbulb Created with Sketch. 2030
    Well, you are currently the poster posting stupid post so I respond to them like I do to others posting the same stupid posts. Are you sure you know how clinical trial work??? If you don't demonstrate safety then you can't advance the clinical trial with increase dosage to give you the best chance of efficacy at OBD. Most clinical trial fail at this stage so for any efficacy seen so early is remarkable, even @Mason14 agreed but then he made a stupid comment that management isn't seeing enough efficacy so are increasing the dosage on the same post lol. That's the whole point of Ph1 clinical trial SAFETY, CSL only saw some efficacy at the end of Ph2 clinical trial and decided to go a head with Ph3 clinical trial which cost them $1B and unsurprisingly it flopped.

    The clinical trials are going as expected and even exceed expectation in the last 12 months so don't you think that's "good management" so I think we are in good hand to negotiate any T/O from BP to maximise value for share holder.
    Last edited by AlCp: 20/12/24
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.4¢
Change
0.003(27.3%)
Mkt cap ! $104.5M
Open High Low Value Volume
1.2¢ 1.4¢ 1.1¢ $293.2K 23.91M

Buyers (Bids)

No. Vol. Price($)
15 4830164 1.3¢
 

Sellers (Offers)

Price($) Vol. No.
1.4¢ 10474572 41
View Market Depth
Last trade - 11.46am 27/06/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.